Cargando…

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases

PURPOSE/OBJECTIVES: Locally recurrent pancreatic cancer is a therapeutic challenge, and aggressive approaches are needed to improve its clinical outcomes. Stereotactic body radiotherapy (SBRT) is a promising treatment for pancreatic cancer with an excellent local control and acceptable toxicity. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Yuxin, Zhu, Xiaofei, Cao, Fei, Xie, Hongliang, Ju, Xiaoping, Cao, Yangsen, Qing, Shuiwang, Jia, Zhen, Gu, Lei, Fang, Fang, Zhang, Huojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593208/ https://www.ncbi.nlm.nih.gov/pubmed/34796108 http://dx.doi.org/10.3389/fonc.2021.729490

Ejemplares similares

Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2017)

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial
por: Zhu, Xiaofei, et al.
Publicado: (2016)

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
por: Zhu, Xiaofei, et al.
Publicado: (2022)

Stereotactic Radiation Therapy (SRT) for Brain Metastases of Multiple Primary Tumors: A Single Institution Retrospective Analysis
por: Gu, Lei, et al.
Publicado: (2019)

Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study
por: Jia, Zhen, et al.
Publicado: (2023)

Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration
por: Cao, Yangsen, et al.
Publicado: (2023)

Correction: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study
por: Jia, Zhen, et al.
Publicado: (2023)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Developments in Stereotactic Body Radiotherapy
por: Haridass, Anoop
Publicado: (2018)

Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer
por: Zhao, Xianzhi, et al.
Publicado: (2018)

Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses
por: Patel, Nisha R., et al.
Publicado: (2014)

Concurrent immunotherapy and re‐irradiation utilizing stereotactic body radiotherapy for recurrent high‐grade gliomas
por: Mahase, Sean S., et al.
Publicado: (2023)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting auto-shells
por: Cao, Yangsen, et al.
Publicado: (2018)

Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer
por: Stanisce, Luke, et al.
Publicado: (2018)

Stereotactic body radiotherapy for solitary spine metastasis
por: Lee, Sunyoung, et al.
Publicado: (2013)

A Survey of Stereotactic Body Radiotherapy in Korea
por: Bae, Sun Hyun, et al.
Publicado: (2015)

Stereotactic body radiotherapy in lung cancer: an update
por: Abreu, Carlos Eduardo Cintra Vita, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Re-irradiation after stereotactic body radiotherapy for spine metastases from hepatocellular carcinoma: a case report
por: BalajiSubramanian, Sitaraman, et al.
Publicado: (2021)

Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence
por: Touati, Ruben, et al.
Publicado: (2023)

Re-irradiation with stereotactic radiotherapy for recurrent high-grade glial tumors
por: Soykut, Ela Delikgoz, et al.
Publicado: (2023)

Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer
por: Huang, Tai-Lin, et al.
Publicado: (2022)

Neuroendocrine Carcinoma of Uterine Cervix: Stereotactic Radiotherapy for Brain Metastasis and Stereotactic Body Radiotherapy for Renal and Pancreatic Metastases
por: Mori, Yoshimasa, et al.
Publicado: (2020)

Phase I study of dose‐escalated stereotactic body radiation therapy for locally advanced pancreatic head cancers: Initial clinical results
por: Qing, Shuiwang, et al.
Publicado: (2021)

Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT)
por: Wu, Trudy C., et al.
Publicado: (2023)

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Stereotactic Body Radiotherapy as an Alternative to Brachytherapy in Gynecologic Cancer
por: Kubicek, Gregory J., et al.
Publicado: (2013)

Stereotactic Body Radiotherapy for Early Stage Lung Cancer
por: Nagata, Yasushi
Publicado: (2013)

Complications from Stereotactic Body Radiotherapy for Lung Cancer
por: Kang, Kylie H., et al.
Publicado: (2015)

Safety of high-dose-rate stereotactic body radiotherapy
por: Stieb, Sonja, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma
por: Mahadevan, Anand, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dmrghj0ok0gol0k4sc8boaobvf